Journal Article Epublish 2 citations
PubMed: 40564910 DOI: 10.3390/ijms26125444
The Design of a Multistage Monitoring Protocol for Dendritic Cell-Derived Exosome (DEX) Immunotherapy: A Conceptual Framework for Molecular Quality Control and Immune Profiling.
Int J Mol Sci 26(12)
Authors: Ramón Gutiérrez-Sandoval, Francisco Gutiérrez-Castro, Natalia Muñoz-Godoy, Ider Rivadeneira, Adolay Sobarzo, Luis Alarcón, Wilson Dorado, Andy Lagos, Diego Montenegro, Ignacio Muñoz, Rodrigo Aguilera, Jordan Iturra, Francisco Krakowiak, Cristián Peña-Vargas, Andrés Toledo
Affiliations
- Department of Oncopathology, OGRD Alliance, Lewes, DE 19958, USA.
- Department of Cancer Research, Flowinmunocell-Bioexocell Group, 08028 Barcelona, Spain.
- Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown KN0802, Saint Kitts and Nevis.
- Departamento de Ciencias Biológicas y Químicas, Facultad de Ciencias, Universidad San Sebastián, Lientur 1457, Concepción 4080871, Chile.
- Department of Molecular Oncopathology, Bioclas, Concepción 4030000, Chile.
Abstract
The increasing complexity of dendritic cell (DC)-derived exosome (DEX) immunotherapy demands structured monitoring protocols capable of translating molecular activity into actionable clinical outputs. This study proposes a standardized, multistage immunomonitoring framework designed to evaluate immune activation, cytokine polarization, and product integrity in DEX-based therapies. The protocol integrates open access methodologies-flow cytometry, cytometric bead array (CBA), and Western blotting-to assess CD69/CD25 activation, Th1/Th2/Th17 cytokine profiles, and vesicle identity across distinct checkpoints. These outputs are consolidated within the Structured Immunophenotypic Traceability Platform (STIP), which applies logic-based classifications (Type I-III) to support reproducible stratification of immune responses. Functional validation was performed through ex vivo co-culture models, enabling real-time interpretation of immune polarization, cytotoxic potential, and batch consistency. These outputs are supported by previous experimental validations published in Cancers and Biomedicines (2025), where PLPC and DC-derived vesicles demonstrated immunological consistency and a phenotypic stratification capacity. This approach provides a scalable monitoring structure that can support personalized treatment decisions, quality assurance workflows, and integration into regulatory documentation (e.g., CTD Module 5.3) for early-phase, non-pharmacodynamic immunotherapies. This conceptual protocol does not aim to demonstrate therapeutic efficacy but to provide a reproducible documentation framework for real-world immune monitoring and regulatory alignment in vesicle-based immunotherapy.
MeSH
Cytokines, Cells, Quality Control, Documentation, Immunotherapy, Exosomes, Therapeutics, Dendritic Cells